Novo Nordisk A/S’s (NVO) “Neutral” Rating Reiterated at The Goldman Sachs Group

The Goldman Sachs Group restated their neutral rating on shares of Novo Nordisk A/S (NYSE:NVO) in a research report released on Monday morning, Marketbeat reports. They currently have a $41.00 target price on the stock, down from their prior target price of $63.00.

NVO has been the subject of several other reports. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Citigroup started coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They issued a “neutral” rating on the stock. CICC Research started coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective for the company. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Five equities research analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $53.93.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $38.51 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a 50-day moving average of $51.96 and a 200-day moving average of $52.58. Novo Nordisk A/S has a one year low of $35.85 and a one year high of $91.90. The company has a market cap of $171.95 billion, a P/E ratio of 11.10 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is presently 23.63%.

Institutional Investors Weigh In On Novo Nordisk A/S

Several large investors have recently added to or reduced their stakes in NVO. Franklin Resources Inc. lifted its holdings in Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after purchasing an additional 13,658,867 shares during the last quarter. Capital International Investors increased its stake in shares of Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after purchasing an additional 6,092,192 shares in the last quarter. Boston Partners bought a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $310,199,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Novo Nordisk A/S by 99.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after buying an additional 4,836,285 shares in the last quarter. Finally, Voloridge Investment Management LLC boosted its holdings in Novo Nordisk A/S by 851.6% in the 4th quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after buying an additional 4,302,126 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley upgraded NVO to Equal‑weight and set a $40 price target, citing that the recent sell‑off has better priced in mid‑term risks — a catalyst for short‑term buying. Morgan Stanley upgrade
• Positive Sentiment: Novo announced significant capacity investments: a $372.5M expansion in Monksland, Athlone (Ireland) and a €432M upgrade to produce oral Wegovy — signals of management backing long‑term growth in obesity/GLP‑1. Monksland expansion Ireland facility upgrade
• Neutral Sentiment: Goldman Sachs reaffirmed a Neutral rating on NVO — supportive of no dramatic re‑rating but not a bullish endorsement. Goldman Sachs reaffirms Neutral
• Negative Sentiment: The U.S. FDA sent Novo a second warning letter ordering it to stop a consumer Ozempic ad, saying the commercial makes false or misleading claims — raises regulatory scrutiny and potential marketing limitations for a core franchise. Reuters: FDA warning
• Negative Sentiment: Industry groups (AHA) are urging HRSA to block Novo’s new claims‑data submission policy affecting 340B hospitals — potential policy & reimbursement friction that could pressure margins or access. AHA on 340B policy
• Negative Sentiment: Investor litigation risk surfaced as Pomerantz LLP opened an investigation into Novo Nordisk investors — a potential headwind if suits follow regulatory or disclosure claims. Pomerantz investor investigation
• Negative Sentiment: Novo said it will halve the U.S. list price of Wegovy in 2027 — direct pricing pressure on a growth driver that may weigh on revenue expectations. Wegovy price cut
• Negative Sentiment: Competitive and generic threats: Aspen expects a Canada nod for a generic Ozempic this year and Roche is publicly targeting share gains in weight‑loss — potential market share and pricing headwinds. Aspen generic Ozempic Roche competition

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.